宜明昂科-B(01541)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01541 宜明昂科-B

未开盘 06-10 16:09:06

3.230

+0.150

+4.87%

最高3.350	最低3.090	成交量202.26万
今开3.170	昨收3.080	日振幅8.44%
总市值13.92亿	流通市值13.57亿	总股本4.31亿
成交额643.29万	换手率0.48%	流通股本4.20亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01541","market":"HK","secType":"STK","nameCN":"宜明昂科-B","latestPrice":3.23,"timestamp":1781078946011,"preClose":3.08,"halted":0,"volume":2022600,"delay":0,"changeRate":0.04870129870129867,"floatShares":420000000,"shares":430999999,"eps":-0.6125493930203215,"marketStatus":"未开盘","change":0.15,"latestTime":"06-10 16:09:06","open":3.17,"high":3.35,"low":3.09,"amount":6432932,"amplitude":0.084416,"askPrice":3.24,"askSize":20600,"bidPrice":3.23,"bidSize":3600,"shortable":0,"etf":0,"ttmEps":-0.6483777537441516,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781141400000},"marketStatusCode":0,"adr":0,"listingDate":1693843200000,"exchange":"SEHK","adjPreClose":3.08,"openAndCloseTimeList":[[1781055000000,1781064000000],[1781067600000,1781078400000]],"volumeRatio":1.5095832338640311,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01541","defaultTab":"news","newsList":[{"id":"1162486730","title":"宜明昂科-B回购52,800股股份，总额约16.93万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1162486730","media":"公告速递","labels":["shareholding","SGX"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162486730?lang=zh_cn&edition=full","pubTime":"2026-06-10 19:46","pubTimestamp":1781091997,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术（上海）股份有限公司于2026年6月10日发布翌日披露报表，公告公司于2026年6月10日在香港联交所场内回购52,800股H股普通股股份。此次回购股份数量占该事件前现有已发行股本约0.0126%，每股价格介乎港币3.12元至3.27元，合共耗资约16.93万港元。本次回购完成后，宜明昂科-B已发行股份总数为420,477,305股，其中419,742,705股为已发行股份、734,600股为库存股份。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宜明昂科-B回购52,800股股份，总额约16.93万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642423403","title":"宜明昂科-B(01541)6月10日斥资16.93万港元回购5.28万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642423403","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642423403?lang=zh_cn&edition=full","pubTime":"2026-06-10 19:44","pubTimestamp":1781091862,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B(01541)发布公告，于2026年6月10日斥资16.93万港元回购5.28万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452760.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01541","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174897767","title":"宜明昂科-B：6月9日回购41.6万股，耗资约129.37万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1174897767","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174897767?lang=zh_cn&edition=full","pubTime":"2026-06-09 18:26","pubTimestamp":1781000801,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术（上海）股份有限公司6月9日向香港联合交易所提交翌日披露报表，公布进行股份回购。据公告，6月9日，公司于香港联交所场内回购416,000股H股，占回购前已发行股份约0.099%。本次回购每股价格介乎3.03港元至3.20港元之间，回购股份的加权平均每股价格为3.1099港元，总涉资1,293,708港元。本次回购完成后，公司于截止6月9日的已发行股份为419,795,505股，库存股份为681,800股，合计420,477,305股。截至目前，已累计购回股份681,800股，占获授权数量约0.158%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宜明昂科-B：6月9日回购41.6万股，耗资约129.37万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185406218","title":"宜明昂科-B 6月8日回购26.58万股，耗资约82.78万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1185406218","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185406218?lang=zh_cn&edition=full","pubTime":"2026-06-08 22:21","pubTimestamp":1780928516,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术（上海）股份有限公司（宜明昂科-B）于2026年6月8日在香港联交所回购H股股份，共回购26.58万股，占该次回购前已发行股份（不含库藏股）总数的约0.0632%。每股回购价格介乎每股3.04港元至3.27港元，合计支付约82.78万港元。回购完成后，公司已发行股份总数维持4.20亿股，其中外部流通股为4.20亿股，库藏股26.58万股。根据股东于2026年5月28日通过的回购授权，公司可回购的股份总数为4315.08万股，本次回购数量约占授权总额的0.0616%。\n公司同时确认已遵守香港联合交易所有限公司证券上市规则及相关法律法规。公告由执行董事、联席公司秘书关梅签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"宜明昂科-B 6月8日回购26.58万股，耗资约82.78万港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641480399","title":"宜明昂科-B(01541)6月8日斥资82.78万港元回购26.58万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2641480399","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641480399?lang=zh_cn&edition=full","pubTime":"2026-06-08 22:19","pubTimestamp":1780928376,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B(01541)发布公告，于2026年6月8日，该公司斥资82.78万港元回购26.58万股股份，每股回购价3.04-3.27港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451690.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01541","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641712197","title":"港股异动 | 宜明昂科-B(01541)涨超7% IMC-002治疗中重度SLE Ib/II期初步数据以壁报形式于EULAR 2026公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2641712197","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641712197?lang=zh_cn&edition=full","pubTime":"2026-06-05 14:19","pubTimestamp":1780640370,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宜明昂科-B涨超7%，截至发稿，涨6.11%，报3.3港元，成交额390.31万港元。消息面上，6月4日，据宜明昂科官微消息，公司宣布，其自主研发的双特异性融合蛋白药物IMC-002，在2026年欧洲抗风湿病联盟年会上以壁报形式公布了其针对中重度活动性系统性红斑狼疮患者的Ib/II期临床试验最新初步结果。据介绍，IMC-002是一款靶向CD20和CD47的双特异性融合蛋白。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450622.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01541","BK1161","BK4077","BK4585","VXUS","BK4588","SLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178023372","title":"宜明昂科-B更新2026年5月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1178023372","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178023372?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:47","pubTimestamp":1780476433,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术（上海）股份有限公司于2026年6月3日发布2026年5月股份变动月报表。该报告期截至2026年5月31日，公司股本结构总体维持稳定，未发生新增发行、购回或注销股份的事项。本次公告显示，公司注册股本本月底合计为人民币431,507,695元，较上月底无变化。其中，上市H股420,477,305股，非上市股份11,030,390股。本次公告由执行董事、联席公司秘书关梅签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640990015","title":"港股异动 | 宜明昂科-B(01541)涨超7% 公布IMM2510治疗IO经治晚期肺鳞癌积极进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2640990015","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640990015?lang=zh_cn&edition=full","pubTime":"2026-06-02 15:12","pubTimestamp":1780384337,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宜明昂科-B(01541)涨超7%，截至发稿，涨7.36%，报3.21港元，成交额2670.97万港元。消息面上，6月1日，宜明昂科宣布，公司自主研发的VEGF×PD-L1双靶点药物珀维拉芙普α（IMM2510）在2026年美国临床肿瘤学会（ASCO）年会上正式公布了其I期临床研究数据（摘要号：8580）。数据显示，IMM2510在经免疫治疗（IO）进展的晚期肺鳞癌患者中，不仅疗效显著，更展现出区别于同类产品的优异安全性。公司指，基于I期研究展现出的积极数据及暴露-效应分析结果，研究已确定20mg/kg Q2W为II期推荐剂量（RP2D），后续III期临床研究正在计划中。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449015.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","VXUS","BK4585","BK1161","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637265312","title":"宜明昂科-B(01541)赎回2.05亿港元的申万产品及认购2.12亿港元的申万宏源理财产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2637265312","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637265312?lang=zh_cn&edition=full","pubTime":"2026-05-22 21:19","pubTimestamp":1779455947,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B(01541)公布，公司已于2026年5月22日通知申万宏源证券(香港)，以现金赎回2.05亿港元的申万产品，即其当时持有的全部申万产品，估计收益约为496.9万港元(即赎回事项产生的未经审计利息收入)。于赎回事项后，集团将不再持有申万宏源证券(香港)任何尚未到期理财产品。此外，于2026年5月22日，公司同意向申万宏源证券(香港)认购金额为2.12亿港元的理财产品。认购事项由集团的内部盈余现金储备提供资金。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445309.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000166","01541","06806","BK0028","BK1147","BK0188","BK0012","BK0276","BK1161","BK1564","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196978420","title":"宜明昂科-B拟于2026年5月22日认购2.12亿港元申万理财产品","url":"https://stock-news.laohu8.com/highlight/detail?id=1196978420","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196978420?lang=zh_cn&edition=full","pubTime":"2026-05-22 21:15","pubTimestamp":1779455721,"startTime":"0","endTime":"0","summary":"宜明昂科-B宣布，计划于2026年5月22日动用2.12亿港元，认购申万宏源旗下的一款理财产品。此举旨在优化公司闲置资金的使用效率，以期在保障资金安全的前提下获取稳健的财务回报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636528108","title":"宜明昂科-B(01541)：IMM0306治疗SLE的II期随机及安慰剂对照试验完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2636528108","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636528108?lang=zh_cn&edition=full","pubTime":"2026-05-19 22:05","pubTimestamp":1779199512,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B(01541)发布公告，IMM0306治疗系统性红斑狼疮 (SLE)的II期随机及安慰剂对照试验顺利完成首例患者给药。预期将招募约90例患者，并按1：1：1的比例随机分配至三个治疗组，分别接受IMM0306(剂量为1.2 mg/kg及1.6 mg/kg)或安慰剂的治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443659.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SLE","01541","BK4077","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636835313","title":"宜明昂科-B(01541.HK)尾盘涨超6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636835313","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636835313?lang=zh_cn&edition=full","pubTime":"2026-05-19 15:31","pubTimestamp":1779175900,"startTime":"0","endTime":"0","summary":"5月19日，宜明昂科-B(01541.HK)尾盘涨超6%，截至发稿，涨5.41%，报3.7港元，成交额231.26万港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605193741895653.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605193741895653.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01541","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636833670","title":"港股异动 | 宜明昂科-B(01541)尾盘涨超6% IMM0306原发性干燥综合征IND申请正式获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2636833670","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636833670?lang=zh_cn&edition=full","pubTime":"2026-05-19 15:26","pubTimestamp":1779175568,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宜明昂科-B尾盘涨超6%，截至发稿，涨5.41%，报3.7港元，成交额231.26万港元。消息面上，宜明昂科近日宣布，公司自主研发的阿沐瑞芙普α，在原发性干燥综合征适应症的新药临床试验申请已正式获得中国国家药品监督管理局批准。这一进展标志着宜明昂科在自身免疫性疾病领域的创新药物研发版图再次迎来重要突破。此次pSS适应症IND的获批，是宜明昂科“自免管线全面推进”战略的又一重要成果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443375.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","VXUS","BK1161","BK4588","01541","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635749711","title":"宜明昂科-B(01541.HK)获董事长田文志增持5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2635749711","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635749711?lang=zh_cn&edition=full","pubTime":"2026-05-14 23:37","pubTimestamp":1778773026,"startTime":"0","endTime":"0","summary":"格隆汇5月14日丨根据联交所最新权益披露资料显示，2026年5月13日，宜明昂科-B(01541.HK)获董事长、首席执行官兼执行董事田文志在场内以每股均价3.87港元增持5万股，涉资约19.35万港元。\r\n\r\n　　增持后，田文志最新持股数目为116,184,090股，持股比例由26.91%上升至27.63%。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202605/14/20260514288847.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202605/14/20260514288847.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260514/32225341.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107596032","title":"宜明昂科-B4月无新增股份发行，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1107596032","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107596032?lang=zh_cn&edition=full","pubTime":"2026-05-07 18:46","pubTimestamp":1778150775,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术（上海）股份有限公司于2026年5月7日发布2026年4月股份变动月报。报告显示，公司在2026年4月期间，无新增股份发行、回购、注销或库藏等变动活动，股本整体保持稳定。月报并显示，公司已符合香港联合交易所有限公司相关上市规则所要求的公众持股量规定。公司同时确认，将继续遵守香港联交所《上市规则》及相关法律法规的要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183634513","title":"宜明昂科-B授予董事股份购回授权，规模最高达已发行股本10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1183634513","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183634513?lang=zh_cn&edition=full","pubTime":"2026-04-30 16:56","pubTimestamp":1777539414,"startTime":"0","endTime":"0","summary":"宜明昂科-B公布股东周年大会通告，董事会建议授予股份购回的一般性授权，最多可回购公司已发行股份总数的10%。截至公司公告日，宜明昂科-B已发行股份总数为431,507,695股，如获股东批准，回购上限约为43,150,769股。本次回购资金将来自公司合规的内部资源，董事会认为此举有助于维护公司价值和股东权益，符合公司以及股东的整体最佳利益。过去十二个月内，宜明昂科-B于联交所的H股最高及最低交易价格分别为每股16.80港元和3.43港元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宜明昂科-B授予董事股份购回授权，规模最高达已发行股本10%","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197342960","title":"宜明昂科生物医药技术（上海）股份有限公司2025年收入翻番，研发投入保持高位","url":"https://stock-news.laohu8.com/highlight/detail?id=1197342960","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197342960?lang=zh_cn&edition=full","pubTime":"2026-04-29 06:20","pubTimestamp":1777414810,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术（上海）股份有限公司于2025年12月31日止年度在肿瘤免疫治疗与相关创新药领域持续深耕，“Drug-by-Design”技术平台推进了多款管线的临床试验与适应症拓展。公司管理层表示，研发与临床成果正助力企业于血液肿瘤、实体瘤及部分自身免疫疾病等多个适应症加速布局。公司现金及现金等价物截至年底达到约6.80亿元人民币，为后续研发和营运提供了更为充足的流动性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宜明昂科生物医药技术（上海）股份有限公司2025年收入翻番，研发投入保持高位","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629097539","title":"港股异动 | 宜明昂科-B(01541)涨超5% 子公司宜明凯尔已完成IMC-003项目MAD研究全部受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2629097539","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629097539?lang=zh_cn&edition=full","pubTime":"2026-04-22 14:47","pubTimestamp":1776840465,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宜明昂科-B涨超5%，截至发稿，涨5.29%，报5.77港元，成交额898.42万港元。消息面上，4月22日，据宜明昂科-B官微消息，公司宣布，其子公司宜明凯尔自主研发的IMC-003/IMM72项目，针对肺动脉高压适应症的健康人群的多次给药剂量递增研究，已顺利完成全部受试者入组。据介绍，与现有同类药物相比，IMC-003具有独特的差异化特性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431820.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK1161","BK4588","BK4585","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127356025","title":"异动解读 | 宜明昂科-B盘中大涨11.52%，研发进展与管线拓展获市场看好","url":"https://stock-news.laohu8.com/highlight/detail?id=1127356025","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127356025?lang=zh_cn&edition=full","pubTime":"2026-04-14 10:16","pubTimestamp":1776133003,"startTime":"0","endTime":"0","summary":"宜明昂科-B今日盘中股价大幅上涨11.52%，引起了市场的高度关注。消息面上，公司近期的研发进展与管线拓展是推动股价上涨的主要因素。有市场分析报告指出，公司作为一家以科研为导向的生物技术公司，拥有丰富的创新候选药物管线，上述进展增强了市场对其长期发展潜力的信心，并给出了积极的目标价评估。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627483659","title":"港股宜明昂科-B大涨超17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627483659","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627483659?lang=zh_cn&edition=full","pubTime":"2026-04-13 10:28","pubTimestamp":1776047320,"startTime":"0","endTime":"0","summary":"4月13日，宜明昂科-B(01541.HK)大涨超17%，截至发稿，涨17.09%，报5.55港元，成交额1143.79万港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604133702619637.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604133702619637.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","VXUS","01541","BK1161","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://immuneonco.com","stockEarnings":[{"period":"1week","weight":0.0287},{"period":"1month","weight":-0.2025},{"period":"3month","weight":-0.3579},{"period":"6month","weight":-0.5031},{"period":"1year","weight":-0.7855},{"period":"ytd","weight":-0.446}],"compareEarnings":[{"period":"1week","weight":-0.0478},{"period":"1month","weight":-0.0757},{"period":"3month","weight":-0.0509},{"period":"6month","weight":-0.0604},{"period":"1year","weight":0.0101},{"period":"ytd","weight":-0.0477}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"宜明昂科生物医药技术（上海）股份有限公司是一家主要从事开发肿瘤免疫疗法的中国公司。该公司的主要业务包括开发用于系统利用先天性和适应性免疫的生物技术，以及开发下一代肿瘤免疫疗法，免疫疗法主要专注于适应性免疫系统。该公司的核心产品IMM01是创新靶向CD47的分子。该公司主要在中国国内和海外市场开展业务。","exchange":"SEHK","name":"宜明昂科-B","nameEN":"IMMUNEONCO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"宜明昂科-B(01541)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供宜明昂科-B(01541)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"宜明昂科-B,01541,宜明昂科-B股票,宜明昂科-B股票老虎,宜明昂科-B股票老虎国际,宜明昂科-B行情,宜明昂科-B股票行情,宜明昂科-B股价,宜明昂科-B股市,宜明昂科-B股票价格,宜明昂科-B股票交易,宜明昂科-B股票购买,宜明昂科-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"宜明昂科-B(01541)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供宜明昂科-B(01541)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}